Santen Pharmaceutical Co Ltd (4536)

Santen Pharmaceutical Co Ltd stock price live, this page displays TYO 4536 stock exchange data. View the 4536 premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Santen Pharmaceutical Co Ltd real time stock price chart below.

What Is the Santen Pharmaceutical Co Ltd Stock Price Today?
The Santen Pharmaceutical Co Ltd stock price today is 1,636.0.

What Is the Stock Symbol for Santen Pharmaceutical Co Ltd?
The stock symbol for Santen Pharmaceutical Co Ltd is "4536."

What Stock Exchange Does Santen Pharmaceutical Co Ltd Trade On?
Santen Pharmaceutical Co Ltd is listed and trades on the Tokyo stock exchange.

Is Santen Pharmaceutical Co Ltd a Good Stock to Buy?
Determining whether Santen Pharmaceutical Co Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.

You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 4536 quote. (ISIN: JP3336000009)

Santen Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker; and netarsudil mesilate and latanoprost, a prostaglandin F2a derivative which is marketing approval phase for the treatment of glaucoma and ocular hypertension. The company also offers sepetaprost, a prostaglandin analogue eye drop drug that is in phase 3 of clinical trials; and latanoprost, an ophthalmic emulsion of a prostaglandin F2a derivative which is filed for marketing approval for the treatment of glaucoma and ocular hypertension. In addition, it provides cyclosporin, an ophthalmic emulsion for the treatment of vernal keratoconjunctivitis; and diquafosol sodium for dry eye treatment. Further, the company develops olodaterol hydrochloride, a ß2 receptor agonist that is in phase 1/2a for the treatment of A dry eye treatment dry eye; sirolimus, an ophthalmic suspension which is in phase 2a for the treatment of 4 Fuchs endothelial corneal dystrophy and meibomian gland dysfunction; epinastine hydrochloride, a histamine H1 receptor antagonist filed for marketing approval for the treatment of allergic conjunctivitis; atropine sulfate, a non-selective muscarinic antagonist that is in phase 2/3 clinical trials for myopia treatment; and AFDX0250BS, an selective muscarinic M2 antagonist which is in phase 2a for the treatment of myopia. Additionally, it offers ursodeoxycholic acid that is in phase 2a of clinical trial for the treatment of presbyopia; and oxymetazoline hydrochloride, a direct-acting alpha adrenergic receptor agonist which is in phase 3 for treatment of ptosis. The company was founded in 1890 and is headquartered in Osaka, Japan.